Early clinical trials in patients with recurrent or metastatic HNSCC—who previously had low prospects of recovery after progression of platinum-based chemotherapy — showed impressive clinical outcomes with the use of the anti-PD-1 antibodies nivolumab or pembrolizumab [10,11]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.